title: HBV mutations in untreated HIV-HBV co-infection using genomic length sequencing.
abstract: HIV infection has a significant impact on the natural progression of hepatitis B virus (HBV) related liver disease. In HIV-HBV co-infected patients, little is known about mutations in the HBV genome, which can influence severity of liver disease. The aim of this study was to characterize and to determine the frequency of known clinically significant mutations in the HBV genomes from HIV-HBV co-infected patients and from HBV mono-infected patients. To accomplish this, genomic length HBV sequencing was performed in highly-active anti-retroviral therapy (HAART)-naïve HIV-HBV co-infected patients (n=74) and in anti-HBV therapy-naïve HBV mono-infected patients (n=55). The frequency of HBV mutations differed between the co-infected and mono-infected patients when comparing patients with the same genotype. BCP mutations A1762T and G1764A were significantly more frequent in HBV genotype C mono-infection and the -1G frameshift was significantly more frequent in co-infection and was only observed in HBV genotype A co-infection. PreS2 deletions were observed more frequently in the setting of co-infection. Further work is needed to determine if these mutational patterns influence the differences in liver disease progression in HIV-HBV co-infected and HBV mono-infected patients.
authors.affiliation: Department of Medicine, Monash University, Melbourne, Victoria, Australia. jennifer.audsley@med.monash.edu.au
authors.forename: Jennifer
authors.initials: J
authors.lastname: Audsley
authors.forename: Margaret
authors.initials: M
authors.lastname: Littlejohn
authors.forename: Lilly
authors.initials: L
authors.lastname: Yuen
authors.forename: Joe
authors.initials: J
authors.lastname: Sasadeusz
authors.forename: Anna
authors.initials: A
authors.lastname: Ayres
authors.forename: Christopher
authors.initials: C
authors.lastname: Desmond
authors.forename: Tim
authors.initials: T
authors.lastname: Spelman
authors.forename: George
authors.initials: G
authors.lastname: Lau
authors.forename: Gail V
authors.initials: GV
authors.lastname: Matthews
authors.forename: Anchalee
authors.initials: A
authors.lastname: Avihingsanon
authors.forename: Eric
authors.initials: E
authors.lastname: Seaberg
authors.forename: Frances
authors.initials: F
authors.lastname: Philp
authors.forename: Melissa
authors.initials: M
authors.lastname: Saulynas
authors.forename: Kiat
authors.initials: K
authors.lastname: Ruxrungtham
authors.forename: Gregory J
authors.initials: GJ
authors.lastname: Dore
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Locarnini
authors.forename: Chloe L
authors.initials: CL
authors.lastname: Thio
authors.forename: Sharon R
authors.initials: SR
authors.lastname: Lewin
authors.forename: Peter A
authors.initials: PA
authors.lastname: Revill
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000627:therapeutic use; D005260:Female; D016679:Genome, Viral; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000821:virology; D006514:Hepatitis B Surface Antigens / Q000235:genetics; D006515:Hepatitis B virus / Q000145:classification / Q000235:genetics*; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000188:drug therapy / Q000821:virology; D006801:Humans; D008297:Male; D008969:Molecular Sequence Data; D009154:Mutation; D011498:Protein Precursors / Q000235:genetics; D017422:Sequence Analysis, DNA
chemical_list: D019380:Anti-HIV Agents; D000998:Antiviral Agents; D006514:Hepatitis B Surface Antigens; D011498:Protein Precursors; C050807:presurface protein 2, hepatitis B surface antigen